- Home
- ORCL vs RVPHW Comparison
ORCL vs RVPHW Comparison
Compare ORCL & RVPHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORCL
- RVPHW
- Stock Information
- Founded
- ORCL 1977
- RVPHW 2018
- Country
- ORCL United States
- RVPHW United States
- Employees
- ORCL N/A
- RVPHW 14
- Industry
- ORCL Computer Software: Prepackaged Software
- RVPHW Biotechnology: Pharmaceutical Preparations
- Sector
- ORCL Technology
- RVPHW Health Care
- Exchange
- ORCL Nasdaq
- RVPHW Nasdaq
- Market Cap
- ORCL N/A
- RVPHW N/A
- IPO Year
- ORCL 1986
- RVPHW N/A
- Fundamental
- Price
- ORCL $205.17
- RVPHW $0.06
- Analyst Decision
- ORCL Buy
- RVPHW
- Analyst Count
- ORCL 28
- RVPHW 0
- Target Price
- ORCL $203.92
- RVPHW N/A
- AVG Volume (30 Days)
- ORCL 15.1M
- RVPHW 22.4K
- Earning Date
- ORCL 06-11-2025
- RVPHW 03-14-2025
- Dividend Yield
- ORCL 0.97%
- RVPHW N/A
- EPS Growth
- ORCL 16.98
- RVPHW N/A
- EPS
- ORCL 4.34
- RVPHW N/A
- Revenue
- ORCL $57,399,000,000.00
- RVPHW N/A
- Revenue This Year
- ORCL $18.60
- RVPHW N/A
- Revenue Next Year
- ORCL $19.22
- RVPHW N/A
- P/E Ratio
- ORCL $47.27
- RVPHW N/A
- Revenue Growth
- ORCL 8.38
- RVPHW N/A
- 52 Week Low
- ORCL $118.86
- RVPHW $0.13
- 52 Week High
- ORCL $216.60
- RVPHW $0.15
- Technical
- Relative Strength Index (RSI)
- ORCL 72.73
- RVPHW N/A
- Support Level
- ORCL $207.48
- RVPHW N/A
- Resistance Level
- ORCL $215.88
- RVPHW N/A
- Average True Range (ATR)
- ORCL 6.03
- RVPHW 0.00
- MACD
- ORCL 3.03
- RVPHW 0.00
- Stochastic Oscillator
- ORCL 78.83
- RVPHW 0.00
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.